Bicara Therapeutics' stock surged 5.55% during pre-market trading on Monday, following the release of its fourth quarter and full year 2025 financial results and business update.

The company was scheduled to report its quarterly earnings before market open, as indicated in the weekly earnings calendar. The actual earnings release, which includes both financial results and a business update, is the likely catalyst for the significant pre-market movement.